Population Health Research Institute
Study List

DREAM (Completed) 
Diabetes REduction Asssessment With Ramipril and Rosiglitazone Medition

< back

 DREAM evaluated whether ramipril and/or rosiglitazone prevent the onset of type 2 diabetes in people with prediabetes and without cardiovascular disease. The trial found no clear benefit for ramipril and a large reduction in incident diabetes with rosiglitazone.  Ramipril did not reduce the incidence of CV and renal events; Rosiglitazone reduced the incidence of renal events, had an overall neutral effect on CV events and increased the incidence of heart failure. Based on the trial results rosiglitazone is suggested as a possible  therapy to reduce the risk for diabetes in some countries.

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment.

Intervention: Ramipril and/or Rosiglitazone; Factorial vs. Placebo.

Length of Study: 4.5 years

# of Patients: 5,269

Patient Populations: Impaired Glucose Tolerance, Cardiovascular Disease, Glucose Metabolism Disorders.


Presentations

DREAM Final Results


Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)

DREAM  Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.

DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-62. Epub 2006 Sep 15.

DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008;31:1007-14. Epub 2008 Feb 11.

Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca